Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review

Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, r...

Full description

Saved in:
Bibliographic Details
Published in:Metabolic brain disease 2020-10, Vol.35 (7), p.1067-1075
Main Authors: Meléndez-Flores, Jesús D., Millán-Alanís, Juan Manuel, González-Martínez, Adrián, Álvarez-Villalobos, Neri Alejandro, Estrada-Bellmann, Ingrid
Format: Article
Language:English
Subjects:
Antidiabetics
Biochemistry
Biomedical and Life Sciences
Biomedicine
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus - drug therapy
Health services
Humans
Hypoglycemic Agents - therapeutic use
Incidence
Information processing
Insulin
Metabolic Diseases
Morris Review Article
Movement disorders
Neurodegenerative diseases
Neurology
Neuroprotection
Neurosciences
Oncology
Parkinson Disease - epidemiology
Parkinson Disease - prevention & control
Parkinson's disease
Patients
Quality assessment
Risk assessment
Sensitizing
Systematic review
Thiazolidinediones - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, reports on the effect of their use have been heterogeneous. We aimed to synthesize the available scientific evidence which assesses the effect of glitazone use in type 2 diabetes patients on PD incidence. A systematic review was performed on multiple electronic databases. Considered for inclusion were studies that assessed the incidence of PD in type 2 diabetes glitazone users. Two reviewers worked independently and in duplicate to assess all studies, extract information and assess the methodological quality in each included study. Four high quality retrospective cohorts fulfilled inclusion criteria. Comparison groups varied across studies. In each study, incidence of PD was lower in glitazone-exposed patients compared to their respective comparison group. Pooled analysis showed lesser risk of PD in ever versus never glitazone users (RR 0.75 [95% C.I. 0.67–0.85; p  
ISSN:0885-7490
1573-7365
DOI:10.1007/s11011-020-00568-5